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Abstract Natural resistance-associated macrophage protein 1
(NRAMP1) is a putative membrane protein that dominates
natural resistance to infection. An NRAMP1-glutathione S-
transferase fusion protein was used to test the ability of the
NRAMP1 NH2-terminal domain to bind to taxol-stabilized
microtubules. Co-sedimentation analysis showed that the fusion
protein binds to microtubules. Although the NH2-terminal
domain of the NRAMP1 molecule has structural homology with
the Pro-rich region of microtubule-associated protein 4 (MAP4),
the presence of the MAP4 microtubule-binding domain fragment
had little effect on the binding of the fusion protein to
microtubules.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Natural resistance, as well as the susceptibility of a host to
infection by intracellular pathogens, is controlled by a single
dominant gene locus, Lsh/Ity/Bcg [1^3]. Vidal et al. [4] isolated
a candidate gene for Bcg from a mouse pre-B cell cDNA
library, and designated it as the ‘natural resistance-associated
macrophage protein gene’ (Nramp). Several Nramp genes have
been cloned [5^7] and have been shown to encode a mem-
brane protein with 10^12 putative transmembrane domains.
This protein is considered to direct the capacity of host mac-
rophages to resist the intracellular replication of ingested par-
asites, such as Mycobacterium. We isolated a human
NRAMP1 cDNA from a human monocyte cDNA library
[6], and showed that human NRAMP1 was expressed in es-
tablished hematopoietic cell lines (monocyte/macrophages and
B- and T-lymphocytes) and human peripheral blood leuko-
cytes (mainly in monocytes) [8,9]. The NH2-terminal region
of human NRAMP1 has structural homology with the SH3-
binding motif and the microtubule-associated protein 4
(MAP4) [10].
MAP4 is a non-neural MAP, which has a microtubule-
binding domain similar to that of the neural MAPs, MAP2,
and tau [11^13]. Human NRAMP1 has structural homology
with the Pro-rich region [10], one of the three subdomains of
the MAP4 microtubule-binding domain [11]. We [14] and
others [15^18] have prepared and characterized several re-
combinant polypeptides of the MAP4 microtubule-binding
domain.
The function of NRAMP1 is unknown at present. Immu-
nohistochemical analysis provided evidence that human
NRAMP1 is located and distributed on the plasma membrane
[10]. In addition to the structural homology to MAP4, we
found that K- and L-tubulins are the only molecules that
were able to associate with the NH2-terminal cytoplasmic do-
main of the human NRAMP1 molecule in a human lympho-
ma cell extract [10]. The lines of evidence suggested that hu-
man NRAMP1 functions as a linker molecule between
phagocytotic vesicles and microtubules [10]. However, there
is no direct evidence that human NRAMP1 binds to micro-
tubules, which are polymers of K- and L-tubulin heterodimers.
Previously, we prepared the GST-NRAMP11V81 protein, a
fusion protein of glutathione S-transferase (GST) and the
NH2-terminal 81 residues of the human NRAMP1 molecule,
to study the in vitro activity of the NH2-terminal cytoplasmic
domain of the NRAMP1 molecule [10]. In this paper, we
examined the interaction between the fusion protein and
taxol-stabilized microtubules in vitro. The ability of the
fusion protein to compete with MAP4 for microtubule bind-
ing was also tested, using the PA4 fragment, a recombinant
peptide corresponding to the microtubule-binding domain of
MAP4.
2. Materials and methods
2.1. Materials
Taxol was supplied by Dr. N. Lomax, of the Natural Products
Branch, National Cancer Institute, Bethesda, MD. It was dissolved
in dimethyl sulfoxide to a stock concentration of 1 mM and was
stored at 320‡C. The PA4 fragment expression plasmid was supplied
by Dr. Murofushi (University of Tokyo). All other materials were of
reagent grade.
2.2. Protein preparations
The GST and GST-NRAMP11V81 were prepared as described [10].
The PA4 fragment was prepared according to Aizawa et al. [15].
Native MAP4 was puri¢ed from bovine adrenal cortex by the method
of Murofushi et al. [19]. Fig. 1 illustrates the schematic structures of
the proteins used in this study, along with a putative structure of the
full-length human NRAMP1.
Bovine brain tubulin was puri¢ed from two-cycled microtubule
protein fractions [20] by the method of Weingarten et al. [21]. The
protein concentration was determined by the method of Lowry et al.
[22] using bovine albumin as the standard. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) was carried out ac-
cording to Laemmli [23], using a 12.5% gel. The gels were stained with
Coomassie brilliant blue R250.
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2.3. Co-sedimentation analysis with taxol-induced microtubules
Escherichia coli crude extracts, containing either GST (GST extract)
or GST-NRAMP11V81 (GST-NRAMP11V81 extract), were prepared
from E. coli JM109 harboring each expression plasmid, according to
Kishi et al. [10]. Each extract (22 Wl) was mixed with puri¢ed tubulin
(¢nal concentration, 15 WM) in 100 MEM bu¡er (100 mM 2-morpho-
linoethanesulfonic acid, 0.5 mM MgSO4, 0.1 mM EGTA, 0.5 mM
GTP, pH 6.8) containing 30 WM taxol (¢nal volume, 50 Wl). The
mixtures were incubated at 37‡C for 30 min, and were centrifuged
at 15 000Ug for 30 min at 30‡C. The precipitates were resuspended
in 50 Wl of an alkaline solution (0.2 M Na2CO3, 0.1 M NaOH), and
the supernatants and the precipitates were subjected to SDS-PAGE.
The two-dimensional band size of the GST-NRAMP11V81 on the
polyacrylamide gels was measured by an imaging analyzer (scanner:
ScanJet 4C, HEWLETT PACKARD, software: NIH image).
2.4. Co-sedimentation analysis with PA4 fragment-induced microtubules
GST-NRAMP11V81 extract was mixed with puri¢ed tubulin (¢nal
concentration, 15 WM) in 100 MEM bu¡er containing 10 WM PA4
fragment. The mixture was incubated at 37‡C for 10 min, and was
centrifuged at 15 000Ug for 10 min at 30‡C. The precipitate was
resuspended in the 100 MEM bu¡er at 0‡C, and was centrifuged at
15 000Ug at 4‡C for 10 min. And further, the supernatant was incu-
bated at 37‡C for 10 min, and was centrifuged at 15 000Ug at 30‡C
for 10 min. The supernatants and the precipitates of each centrifuga-
tion step were subjected to SDS-PAGE.
2.5. Competition analysis
Various concentrations of the PA4 fragment were mixed with puri-
¢ed tubulin (¢nal concentration, 15 WM) in phosphate bu¡er (10 mM
sodium phosphate, 6 mM MgSO4, 0.5 mM GTP, pH 6.8) containing
30 WM taxol (¢nal volume, 50 Wl). Microtubules were allowed to
polymerize by an incubation at 37‡C for 15 min. Then, either
MAP4 or the GST-NRAMP11V81 (¢nal concentration, 5 WM) plus
glutathione (¢nal concentration, 50 mM) was added to the mixtures,
and then the mixtures were incubated for an additional 30 min at
37‡C. After centrifugation at 15 000Ug at 30‡C for 30 min, the pre-
cipitates were resuspended in 50 Wl of an alkaline solution, and sub-
jected to SDS-PAGE. The two-dimensional band sizes of the GST-
NRAMP11V81, MAP4, and the PA4 fragment on the polyacrylamide
gels were measured by an imaging analyzer, as described above.
3. Results
3.1. Binding of GST-NRAMP11V81 to taxol-stabilized
microtubules
To investigate the possibility of an NRAMP1-microtubule
interaction, we ¢rst tested whether the GST-NRAMP11V81
co-sediments in vitro with taxol-stabilized microtubules, using
the E. coli crude extract containing GST-NRAMP11V81 (Fig.
2).
Tubulin polymerizes in the presence of taxol, and the re-
constituted microtubules can be precipitated by centrifugation
(Fig. 2, lane 1). If the GST-NRAMP11V81 binds to micro-
tubules, then GST-NRAMP11V81 would co-precipitate with
the microtubules under these conditions. Lanes 2 and 3 are
the control studies: Under the same conditions as in lane 1,
the GST alone was recovered in the supernatant, as was the
GST-NRAMP11V81. Trace amounts of both proteins were
observed in the precipitates, suggesting that the GST and
the GST-NRAMP11V81 are labile against the warming proc-
ess (37‡C, 30 min). When each extract was mixed with micro-
tubules, about half of the added GST-NRAMP11V81 co-sedi-
mented with the microtubules (lane 5), while most of the GST
was recovered in the supernatant (lane 4). This indicated that
the GST-NRAMP11V81 has an activity to bind to microtu-
bules in vitro, and that the NRAMP1 portion in the fusion
protein is responsible for the binding activity.
The quantitation by imaging analyzer revealed that the con-
centration of added GST-NRAMP11V81 was 10 WM and that
of the bound GST-NRAMP11V81 was 4 WM. The binding
stoichiometry was 0.3 mol of GST-NRAMP11V81/mol of tu-
bulin dimer. In the same condition, 7 WM of the PA4 fragment
bound to microtubules and the stoichiometry was 0.5 mol of
PA4 fragment/mol of tubulin dimer (data not shown). The
di¡erence in the apparent stoichiometry is most likely due
to the di¡erence in the binding a⁄nities, namely, the binding
a⁄nity of the GST-NRAMP11V81 is smaller than that of the
PA4 fragment.
3.2. Puri¢cation of the GST-NRAMP11V81
To analyze the details of the NRAMP1-microtubule inter-
action, the GST-NRAMP11V81 was puri¢ed using glutathione
Sepharose 4B (Pharmacia Biotech), according to the supplier’s
manual. We attempted to digest the puri¢ed GST-
NRAMP11V81 with Factor Xa protease to remove the GST
portion of the fusion protein. However, the puri¢ed GST-
NRAMP11V81 became insoluble instantly under the digestion
conditions used in this study (50 mM Tris-HCl, 150 mM
NaCl, 1 mM CaCl2, pH 7.5), and appropriate digestion con-
ditions were not found. In addition, the puri¢ed GST-
NRAMP11V81 was extremely unstable in the Good’s bu¡er
system, which is commonly used for in vitro microtubule re-
assembly analysis [24].
The puri¢ed GST-NRAMP11V81 was found to be stable in
phosphate bu¡er in the presence of 50 mM reduced gluta-
thione. This condition was inappropriate for the digestion
with Factor Xa protease, but it is worth noting that phos-
phate bu¡er is used by several groups for microtubule assem-
bly experiments [25,26]. We also con¢rmed, by electron micro-
scopy, that the structure of the microtubules was normal in
the phosphate bu¡er system used in this study (data not
shown). In the following experiment, we tested the microtu-
bule-binding activity of the puri¢ed GST-NRAMP11V81 using
the phosphate bu¡er system.
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Fig. 1. Schematic representation of the putative structure of the
NRAMP1, the GST fusion protein GST-NRAMP11V81, MAP4,
and the PA4 fragment.
K. Tokuraku et al./FEBS Letters 428 (1998) 63^6764
3.3. Competition analysis of GST-NRAMP11V81 and
PA4 fragment for binding to microtubules
By measuring the amounts of MAPs that co-sedimentated
with the microtubules, one can analyze the details of the
MAP-microtubule interaction. We have determined the disso-
ciation constant and the binding stoichiometry of MAP4-
truncated fragments to microtubules (Tokuraku, K., Katsuki,
M., Nakagawa, H. and Kotani, S., manuscript in prepara-
tion). However, these biochemical properties are usually de-
termined in the Good’s bu¡er system. So, even if we deter-
mined these properties of the GST-NRAMP11V81 in the
phosphate bu¡er, they would not be comparable with those
of other microtubule-associated proteins, because of the dif-
ferent bu¡er systems. Therefore, the competition between
GST-NRAMP11V81 and other known MAPs was analyzed
instead.
The PA4 fragment is a truncated fragment of MAP4, and
contains its microtubule-binding domain (Fig. 1). The binding
of the PA4 fragment to microtubules was analyzed, and re-
vealed that this fragment still has full microtubule-binding
activity (Tokuraku, K., Katsuki, M., Nakagawa, H. and Ko-
tani, S., manuscript in preparation). The activity of the PA4
fragment in the phosphate bu¡er was also examined, and the
fragment was found to co-sediment with the microtubules in
the same manner as with the Good’s bu¡er system, although
the amount that sedimented was slightly decreased (data not
shown).
When the PA4 fragment was added to either the MAP4-
microtubule mixture or the GST-NRAMP11V81-microtubule
mixture, the amount of the PA4 fragment that bound to the
microtubules increased with increasing concentrations of the
added fragment, and the binding was saturated at about
10 WM (Fig. 3a and b, closed circles). The binding of intact
MAP4 decreased as the concentration of the PA4 fragment
increased (Fig. 3a, open circles), indicating that the PA4 frag-
ment competed with MAP4 for binding sites on the micro-
tubules. On the other hand, the binding of the GST-
NRAMP11V81 to the microtubules remained una¡ected
throughout the examined concentration range (Fig. 3b,
squares). The binding of PA4 fragment was also una¡ected
by the presence of GST-NRAMP11V81 : 100% binding of the
PA4 fragment could be obtained without a¡ecting the binding
of the GST-NRAMP11V81 (Fig. 3b).
3.4. Binding of GST-NRAMP11V81 to PA4 fragment-induced
microtubules
We then examined whether the GST-NRAMP11V81 co-
exists with the PA4 fragment-induced microtubules through
assembly cycles, since there is no competition between the
PA4 fragment and the GST-NRAMP11V81 (Fig. 3).
The GST-NRAMP11V81 extract was mixed with puri¢ed
tubulin and the PA4 fragment, and the microtubule protein
fraction was prepared by the assembly-disassembly cycles
(Fig. 4). Lanes 1 and 2 are supernatants and precipitates of
the ¢rst assembly cycle. The GST-NRAMP11V81 co-sedimen-
tated with the microtubules (lane 1) and a large quantity of
the GST-NRAMP11V81 was recovered in the supernatant
after cold treatment (lane 2), indicating that the GST-
NRAMP11V81 cycles with microtubule proteins. Lane 3 are
the supernatant and the precipitate after the second assembly
step. In this step, the GST-NRAMP11V81 was the only pro-
tein in the E. coli extract that co-sedimentated with micro-
tubules. All the other visible bands were the degradation
products of the PA4 fragment, as revealed by immuno-blot-
ting experiments (data not shown). Because of the proteolytic
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Fig. 3. Competition analysis of GST-NRAMP11V81 and the PA4
fragment for binding to microtubules. Various concentrations of the
PA4 fragment and a constant concentration (5 WM) of either MAP4
(a) or GST-NRAMP11V81 (b) were mixed with microtubules. The
mixtures were centrifuged, and then the precipitations were sub-
jected to SDS-PAGE. The amounts of sedimentated MAP4 (open
circles), GST-NRAMP11V81 (squares), and the PA4 fragment
(closed circles) are plotted against the amount of added PA4 frag-
ment. ‘100%’ in the ordinate represents the binding amounts of the
PA4 fragment (10 WM) alone, MAP4 (5 WM) alone, or GST-
NRAMP11V81 (5 WM) alone.
Fig. 2. Co-sedimentation analysis of the GST-NRAMP11V81 with
taxol-induced microtubules. Each sample was centrifuged, and then
the supernatants (S) and the precipitations (P) were subjected to
SDS-PAGE. Lane 1, tubulin alone; lane 2, GST extract alone; lane
3, GST-NRAMP11V81 extract alone; lane 4, GST extract mixed
with microtubules; lane 5, GST-NRAMP11V81 extract mixed with
microtubules. The numbers on the left side indicate the positions of
the marker proteins: fusion of E. coli maltose-binding protein
(MBP) and E. coli L-galactosidase (175 kDa), fusion of MBP and
paramyosin (83 kDa), bovine glutamic dehydrogenase (62 kDa),
rabbit aldolase (48 kDa), rabbit triosephosphate isomerase (33 kDa),
bovine L-lactoglobulin A (25 kDa), and chicken lysozyme (17 kDa).
Tb, GN, and G show the positions of tubulin, GST-NRAMP11V81,
and GST, respectively.
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activity in the E. coli extract, the cycling experiment could not
be furthered.
4. Discussion
In this paper, we demonstrated that the GST-
NRAMP11V81 has the microtubule-binding activity in vitro.
Competition analysis indicated that the GST-NRAMP11V81
could not compete with PA4 fragment for binding to micro-
tubules in this assay system. Since it was demonstrated here
that the cytoplasmic domain of human NRAMP1 binds to
microtubules, the hypothesis that NRAMP1 mediates between
endosomes and microtubules [10] was con¢rmed.
The MAP2, MAP4, and tau proteins share a homologous
sequence in their carboxyl-terminal basic domains [11], and
these MAPs are considered to interact with microtubules in
a similar fashion. In fact, MAP2 and tau, but not MAP1,
compete with the PA4 fragment for microtubule binding (Ku-
roya, T., Tokuraku, K., Katsuki, M. and Kotani, S., manu-
script in preparation). Competition between tau and the mi-
crotubule-binding domain fragment of MAP2 has also been
reported [27]. The NH2-terminal cytoplasmic domain of hu-
man NRAMP1 has an amino acid sequence homologous to
the Pro-rich region in MAP4 [10], yet our data show that
GST-NRAMP11V81 did not compete with the PA4 fragment,
indicating that the microtubule-binding mechanism of
NRAMP1 is di¡erent not only from that of MAP4, but
also from those of MAP2 and tau.
Among the three subdomains (the AP sequence region, the
Pro-rich region, and the tail region) in the microtubule-bind-
ing domains of MAP2, MAP4 and tau, the most homologous
region is the AP sequence region [11]. This region is essential
to promote tubulin polymerization and to bind to microtubule
[15], and binding site in tubulin has been revealed [28,29].
Although the Pro-rich region of MAP2, MAP4 and tau
have similar amino acid compositions, signi¢cant sequence
homology is not observed among the Pro-rich region of the
three MAPs [11]. Our result, which shows that the NRAMP1
and MAP4 do not compete in spite of the sequence homology,
supports the idea that the Pro-rich region does not play a
dominant role in determining the binding speci¢city.
Other well-known microtubule-associated proteins are
MAP1 and the microtubule-dependent motor proteins
[30,31], but the NH2-terminal cytoplasmic domain of
NRAMP1 has no structural homology with these proteins
[10]. The motor proteins contain the ATP-binding domain
in addition to the microtubule-binding domain. NRAMP1
does not contain the so-called ATP-binding cassette [10],
and we con¢rmed that ATP had no e¡ect on the binding of
GST-NRAMP11V81 to microtubules (data not shown). Con-
sequently, NRAMP1 is neither a MAP1-like MAP nor a mo-
tor protein. Further, while all of the known MAPs are soluble
proteins, NRAMP1 is a polytrophic integral membrane pro-
tein with structural features common to prokaryotic and eu-
karyotic transporter proteins [10]. These lines of evidence in-
dicate that NRAMP1 is a new microtubule-associated protein
with unique characteristics. It may form a new category of
MAPs.
Intracellular pathogens are taken up in phagocytic macro-
phages, and are killed after phagolysosomal fusion, which is
assumed to be controlled by a single dominant gene locus,
designated Lsh/Ity/Bcg. Since the candidate gene product of
Bcg, NRAMP1, shows microtubule-binding activity, this pro-
tein could mediate microtubule-dependent phagosome and/or
lysosome transport. Whether the motor activity resides in
NRAMP1 itself or in another associated protein(s) remains
to be solved. Recently, in vivo phosphorylation of NRAMP1
was demonstrated [32]. Studies of the phosphorylation-de-
pendent regulation of the NRAMP1-microtubule interaction
are now in progress.
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